Presumed masitinib-induced nephrotic syndrome and azotemia in a dog

Lauren Devine, David J. Polzin

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Masitinib mesylate is a tyrosine-kinase inhibitor approved for the treatment of nonresectable or recurrent, Grade 2 or 3 mast cell tumors in dogs. This report describes nephrotic syndrome and acute kidney injury attributed to masitinib and illustrates the need for regular monitoring of serum creatinine concentration, urinalysis, and urine protein: creatinine ratio during its use.

Original languageEnglish (US)
Pages (from-to)752-756
Number of pages5
JournalCanadian Veterinary Journal
Issue number7
StatePublished - Jul 2016


Dive into the research topics of 'Presumed masitinib-induced nephrotic syndrome and azotemia in a dog'. Together they form a unique fingerprint.

Cite this